NCT05177185: A Phase 2 Prospective Trial of Hippocampal-Sparing Stereotactic Radiosurgery Treatment of Brain Metastases Using CyberKnife

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have brain metastase(s) outside of a 5-mm margin around the hippocampus
Exclusions: Patients with  radiation therapy to the brain or whole brain radiation therapy, unless radiosurgery with hippocampal-sparing; Patients with definitive leptomeningeal metastases

Comments are closed.

Up ↑